JP2024519545A - B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma - Google Patents
B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma Download PDFInfo
- Publication number
- JP2024519545A JP2024519545A JP2023573168A JP2023573168A JP2024519545A JP 2024519545 A JP2024519545 A JP 2024519545A JP 2023573168 A JP2023573168 A JP 2023573168A JP 2023573168 A JP2023573168 A JP 2023573168A JP 2024519545 A JP2024519545 A JP 2024519545A
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- cell
- cells
- subject
- specific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194470P | 2021-05-28 | 2021-05-28 | |
| US63/194,470 | 2021-05-28 | ||
| US202163209694P | 2021-06-11 | 2021-06-11 | |
| US63/209,694 | 2021-06-11 | ||
| PCT/EP2022/064362 WO2022248642A1 (en) | 2021-05-28 | 2022-05-26 | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519545A true JP2024519545A (ja) | 2024-05-15 |
| JP2024519545A5 JP2024519545A5 (cg-RX-API-DMAC7.html) | 2025-05-26 |
Family
ID=82115891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573168A Pending JP2024519545A (ja) | 2021-05-28 | 2022-05-26 | B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220411525A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347039A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240014482A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119679935A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022281104A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024822A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221399A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014139A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022248642A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| EP4426437A4 (en) | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018201051A1 (en) * | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
-
2022
- 2022-05-26 KR KR1020237044376A patent/KR20240014482A/ko active Pending
- 2022-05-26 US US17/825,123 patent/US20220411525A1/en not_active Abandoned
- 2022-05-26 BR BR112023024822A patent/BR112023024822A2/pt not_active Application Discontinuation
- 2022-05-26 CA CA3221399A patent/CA3221399A1/en active Pending
- 2022-05-26 WO PCT/EP2022/064362 patent/WO2022248642A1/en not_active Ceased
- 2022-05-26 EP EP22731534.8A patent/EP4347039A1/en active Pending
- 2022-05-26 AU AU2022281104A patent/AU2022281104A1/en not_active Abandoned
- 2022-05-26 MX MX2023014139A patent/MX2023014139A/es unknown
- 2022-05-26 JP JP2023573168A patent/JP2024519545A/ja active Pending
- 2022-05-26 CN CN202411436609.3A patent/CN119679935A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018201051A1 (en) * | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
Non-Patent Citations (3)
| Title |
|---|
| BLOOD ADV, vol. vol. 4(18), JPN6026020764, 21 September 2020 (2020-09-21), pages 4538 - 4549, ISSN: 0005869186 * |
| BLOOD, vol. vol. 132(Supplement_1), JPN6026020763, 2018, pages 3225, ISSN: 0005869185 * |
| BLOOD, vol. vol. 134(Supplement_1), JPN6026020762, 2019, pages 1580, ISSN: 0005869184 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023024822A2 (pt) | 2024-02-20 |
| WO2022248642A1 (en) | 2022-12-01 |
| US20220411525A1 (en) | 2022-12-29 |
| CA3221399A1 (en) | 2022-12-01 |
| CN119679935A (zh) | 2025-03-25 |
| EP4347039A1 (en) | 2024-04-10 |
| KR20240014482A (ko) | 2024-02-01 |
| MX2023014139A (es) | 2023-12-13 |
| AU2022281104A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202208429A (zh) | 用於治療多發性骨髓瘤之方法 | |
| US20240209061A1 (en) | Fusion proteins and uses thereof | |
| AU2016369537A1 (en) | Antibody molecules to PD-1 and uses thereof | |
| CN110312525A (zh) | T细胞重定向多功能抗体与免疫检查点调节剂的组合及其用途 | |
| JP2016534090A (ja) | Cd38アゴニストの医学的使用 | |
| TW202340247A (zh) | 結合nkg2d、cd16、及5t4之蛋白質 | |
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| WO2022058445A1 (en) | Methods for treating multiple myeloma | |
| JP2023517794A (ja) | 抗tnfr2抗体及びその使用 | |
| US20220411525A1 (en) | Bcma as a target for t cell redirecting antibodies in b cell lymphomas | |
| EP3737410A1 (en) | Anti-siglec-7 antibodies having reduced effector function | |
| CA3253669A1 (en) | Anti-CD39 antibodies and their use | |
| JP2024097985A (ja) | 抗gitr抗体およびその使用 | |
| JP7533330B2 (ja) | Pd-1/cd3二重特異性タンパク質による血液がん治療 | |
| CN118043070A (zh) | Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 | |
| CA3211179A1 (en) | Anti-human cxcr5 antibody and uses thereof | |
| RU2788092C2 (ru) | Молекулы антител к pd-1 и их применения | |
| HK40103924A (en) | Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies | |
| EA050839B1 (ru) | Способы лечения множественной миеломы | |
| HK40092079A (en) | Anti-tnfr2 antibody and uses thereof | |
| CA3124168A1 (en) | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20241218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250516 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250516 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260526 |